Clinical Trials
12
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:7
Phase 2:3
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (58.3%)Phase 2
3 (25.0%)Phase 3
2 (16.7%)A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT06859762
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06629597
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT06612151
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: intravenous (IV) infusion
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT06459973
- Locations
- 🇨🇳
Jilin Provincial Cancer Hospital, Changchun, Jilin, China
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Phase 2
Recruiting
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Drug: YL202 should be intravenously infused
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06439771
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- Next
News
No news found